[go: up one dir, main page]

DE60215682D1 - AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ - Google Patents

AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ

Info

Publication number
DE60215682D1
DE60215682D1 DE60215682T DE60215682T DE60215682D1 DE 60215682 D1 DE60215682 D1 DE 60215682D1 DE 60215682 T DE60215682 T DE 60215682T DE 60215682 T DE60215682 T DE 60215682T DE 60215682 D1 DE60215682 D1 DE 60215682D1
Authority
DE
Germany
Prior art keywords
chronic pain
derivatives
cancer
azaoxoindol
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60215682T
Other languages
English (en)
Other versions
DE60215682T2 (de
Inventor
E Lackey
R Wood Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE60215682D1 publication Critical patent/DE60215682D1/de
Publication of DE60215682T2 publication Critical patent/DE60215682T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60215682T 2001-09-27 2002-09-24 AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ Expired - Fee Related DE60215682T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32601201P 2001-09-27 2001-09-27
US326012P 2001-09-27
PCT/US2002/030150 WO2003027111A1 (en) 2001-09-27 2002-09-24 Chemical compounds

Publications (2)

Publication Number Publication Date
DE60215682D1 true DE60215682D1 (de) 2006-12-07
DE60215682T2 DE60215682T2 (de) 2007-09-06

Family

ID=23270442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215682T Expired - Fee Related DE60215682T2 (de) 2001-09-27 2002-09-24 AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ

Country Status (7)

Country Link
US (2) US7015231B2 (de)
EP (1) EP1430053B1 (de)
JP (1) JP2005508337A (de)
AT (1) ATE343575T1 (de)
DE (1) DE60215682T2 (de)
ES (1) ES2275021T3 (de)
WO (1) WO2003027111A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339680A1 (de) 2000-09-01 2003-09-03 Glaxo Group Limited Substituierte oxindolderivate als tyrosinkinaseinhibitoren
JP2004508366A (ja) 2000-09-01 2004-03-18 グラクソ　グループ　リミテッド オキシインドール誘導体
WO2003027111A1 (en) * 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds
RS52061B (en) 2005-02-04 2012-04-30 Astrazeneca Ab PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
CA2598076A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
DK1853588T3 (da) 2005-02-16 2008-09-15 Astrazeneca Ab Kemiske forbindelser
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2008013400A (es) 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
MX2010004499A (es) 2007-10-24 2010-05-20 Astellas Pharma Inc Compuesto de azolcarboxamida o sal de el.
JP5240205B2 (ja) 2008-01-11 2013-07-17 アステラス製薬株式会社 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
ES2496093T3 (es) * 2010-04-15 2014-09-18 Merck Patent Gmbh Proceso para la preparación de hidroquinonas
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
CN103804273B (zh) * 2014-01-27 2016-06-15 贵州大学 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
MA39286A (fr) 2014-09-17 2016-03-24 Mundipharma International Corporation Ltd Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels
WO2016089760A1 (en) 2014-12-02 2016-06-09 Ignyta, Inc. Combinations for the treatment of neuroblastoma
CA3008663A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations of a selective tyrosine kinase inhibitor (tki) with a mek or erk inhibitor for the treatment of cancer
CN110913842A (zh) 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
WO2003027111A1 (en) * 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
US20060128745A1 (en) 2006-06-15
EP1430053B1 (de) 2006-10-25
DE60215682T2 (de) 2007-09-06
WO2003027111A1 (en) 2003-04-03
US20040198766A1 (en) 2004-10-07
ATE343575T1 (de) 2006-11-15
JP2005508337A (ja) 2005-03-31
EP1430053A1 (de) 2004-06-23
ES2275021T3 (es) 2007-06-01
US7015231B2 (en) 2006-03-21

Similar Documents

Publication Publication Date Title
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
ATE240328T1 (de) Substituierte azaoxindolederivate
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
DE60208792D1 (de) Tyrosin-kinase inhibitoren
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
IS6501A (is) Pyrrólafleiður 2-indólínón prótín kínasa hindra
YU84603A (sh) Novi inhibitori tirozin kinaze
EE200200123A (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
ATE381557T1 (de) Rho-kinase inhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE554087T1 (de) Neue kinaseinhibitoren
ATE353888T1 (de) Chinazolinderivate
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
HN2004000150A (es) Pirazoles como inhibidores de factor de necrosis tumoral
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
ATE238981T1 (de) Antitumorwirkstoffe
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
BRPI0411126A (pt) derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
BRPI0511826A (pt) derivados de 2,4-diaminotiazol-5-ona
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
DK1687642T3 (da) Screeningsfremgangsmåder til kombinationer af biologiske forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee